AMIXHealthcare · Medical DevicesThe 2 Wall Street analysts covering Autonomix Medical, Inc. hold a median 12-month price target of $59 — +1609.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 14 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Autonomix Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (97): Smaller than most of the companies we track.
Value (2): The shares cost a lot relative to the profits and assets behind them.
The rank is the raw material. Whether the rules would actually own Autonomix Medical, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on AMIX, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
The green dot is the last close — the median target sits +1609.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 17 Feb 2026 | Maxim Group | Maintains | Buy | $5.00 → $2.00 |
| 29 Apr 2025 | Maxim Group | Initiates | Buy | — |
| 3 Sept 2024 | Ladenburg Thalmann | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 87% of US stocks
Cheaper than 60% of US stocks
Higher than 35% of US stocks
Higher than 30% of US stocks
Higher than 6% of US stocks
Higher than 2% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AMIX appears on the weeks it earns a place.
Autonomix Medical announced results from a preclinical study showing its technology can detect, localize, and confirm changes in renal neural activity.
Why it matters — The data support continued development of the company's physiology-guided renal denervation approach, a key pipeline program for AMIX.
The 2 Wall Street analysts covering Autonomix Medical, Inc. have a median 12-month price target of $59, with estimates ranging from $42 to $76. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering Autonomix Medical, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Autonomix Medical, Inc. 14 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, Autonomix Medical, Inc. ranks 14 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (97 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies +1609.3% from the last close, and Ticker Nerd's factor model ranks Autonomix Medical, Inc. 14 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Autonomix Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AMIX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $42 to $76 over the next 12 months.
Autonomix Medical Inc. is a medical device company developing precision nerve-targeted therapies to treat diseases involving the peripheral nervous system.
The most recent item we track (GlobeNewsWire, 24 July 2026): "Autonomix Medical Demonstrates Renal Nerve Sensing and Neural Activity Change in Preclinical Study". Autonomix Medical announced results from a preclinical study showing its technology can detect, localize, and confirm changes in renal neural activity.
Autonomix Medical Inc. is a medical device company developing precision nerve-targeted therapies to treat diseases involving the peripheral nervous system. Its first-in-class platform technology features a proprietary catheter-based microchip sensing array that detects and differentiates neural signals with ultra-high sensitivity and on-site data processing, surpassing existing technologies. This enables real-time identification of target nerves, followed by proprietary radio frequency ablation to precisely disable them, and verification of treatment efficacy in a minimally invasive transvascular procedure. Initially focused on pain management for pancreatic cancer patients, the platform addresses unmet needs in chronic pain by offering targeted denervation as an alternative to opioids or invasive methods. With potential applications across cardiology, hypertension, pulmonology, gastroenterology, and interventional pain management, Autonomix Medical Inc. equips physicians with innovative tools for accurate diagnosis and therapy. Headquartered in The Woodlands, Texas, the company advances this breakthrough system protected by a global intellectual property portfolio.
CEO Mr. Bradley Hauser · 8 employees · United States · https://autonomix.com